Can a new pill tame HIV? early trial puts ACC017 to the test
NCT ID NCT06719310
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This early-stage trial is testing an experimental HIV drug called ACC017 in adults with HIV-1 who have never taken HIV medication. The study aims to see if the drug is safe, tolerable, and effective at lowering the amount of virus in the blood, both when used alone and when combined with another HIV treatment (FTC/TAF). Participants will be randomly assigned to receive one of three doses of ACC017 or a placebo, and the trial will monitor side effects and viral load changes over about a month.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ACC017, an experimental integrase inhibitor drug, tested alone and in combination with FTC/TAF
- What this could lead to
- If successful, this could lead to a new treatment option for HIV that helps control the virus with fewer side effects or resistance issues.
- What could go wrong
- This is an early-stage trial with a small number of participants, so results may not hold up in larger studies. The drug may also cause side effects or fail to suppress the virus effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTION, HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Ditan Hospital, Capital Medical University
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.